What is HC Wainwright’s Forecast for MetaVia Q3 Earnings?

MetaVia Inc. (NASDAQ:MTVA) – HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for MetaVia in a note issued to investors on Monday, August 10th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.93) for the quarter, up from their prior forecast of ($0.96). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($2.78) per share. HC Wainwright also issued estimates for MetaVia’s Q4 2026 earnings at ($0.98) EPS, FY2026 earnings at ($3.61) EPS, FY2027 earnings at ($4.51) EPS, FY2028 earnings at ($2.67) EPS, FY2029 earnings at ($2.20) EPS and FY2030 earnings at ($1.85) EPS.

Several other research firms also recently weighed in on MTVA. Wall Street Zen upgraded MetaVia to a “sell” rating in a research note on Saturday, June 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $20.00.

MetaVia Trading Down 0.7%

NASDAQ:MTVA opened at $1.42 on Wednesday. The stock has a 50-day moving average price of $1.67 and a 200 day moving average price of $1.71. The stock has a market capitalization of $7.33 million, a P/E ratio of -0.27 and a beta of 0.95. MetaVia has a 12-month low of $0.97 and a 12-month high of $19.03.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08).

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent reporting period. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.